[
  {
    "ts": null,
    "headline": "GARP: Growth ETF With A Solid Track Record",
    "summary": "iShares MSCI USA Quality GARP ETF holds 135 growth stocks weighted based on value and quality. Read the full ETF analysis and more like it here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=effd3783a0b241fa2ff614b4a6737f5f25dd55a40fa870fdf54248400d4f340f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748884827,
      "headline": "GARP: Growth ETF With A Solid Track Record",
      "id": 134965105,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182410275/image_182410275.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "iShares MSCI USA Quality GARP ETF holds 135 growth stocks weighted based on value and quality. Read the full ETF analysis and more like it here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=effd3783a0b241fa2ff614b4a6737f5f25dd55a40fa870fdf54248400d4f340f"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference",
    "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=d793d985ac6a84767ce1bd1a5f3dbdaa1cd86ce9ff2848313c822f5eec96cbdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748872800,
      "headline": "Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference",
      "id": 134949682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=d793d985ac6a84767ce1bd1a5f3dbdaa1cd86ce9ff2848313c822f5eec96cbdd"
    }
  },
  {
    "ts": null,
    "headline": "Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended P",
    "url": "https://finnhub.io/api/news?id=21ac380e96dc234eba5fcac9617872a9ebbd92f55dbca59bd88e2ff3cf41d879",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748865600,
      "headline": "Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting",
      "id": 134937061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended P",
      "url": "https://finnhub.io/api/news?id=21ac380e96dc234eba5fcac9617872a9ebbd92f55dbca59bd88e2ff3cf41d879"
    }
  },
  {
    "ts": null,
    "headline": "Weight Loss Drug ETF (THNR) Hits New 52-Week High",
    "summary": "THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?",
    "url": "https://finnhub.io/api/news?id=7c1cf7e380603cc6cd95fe0e6a316d6ad89ade8f83831e533fa67e3eab048a41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748862720,
      "headline": "Weight Loss Drug ETF (THNR) Hits New 52-Week High",
      "id": 134937062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?",
      "url": "https://finnhub.io/api/news?id=7c1cf7e380603cc6cd95fe0e6a316d6ad89ade8f83831e533fa67e3eab048a41"
    }
  },
  {
    "ts": null,
    "headline": "Could Viking Therapeutics Become the Next Eli Lilly?",
    "summary": "Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications.  Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete with Eli Lilly's Zepbound.  The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.",
    "url": "https://finnhub.io/api/news?id=bcbd055db916afc0c680f44a5685a2c6bad5b78abcbdd48b40c9d03a2f8e4c41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748861100,
      "headline": "Could Viking Therapeutics Become the Next Eli Lilly?",
      "id": 134937063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications.  Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete with Eli Lilly's Zepbound.  The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.",
      "url": "https://finnhub.io/api/news?id=bcbd055db916afc0c680f44a5685a2c6bad5b78abcbdd48b40c9d03a2f8e4c41"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Presents First Clinical Data For Its Investigational, Next-Generation Fr?",
    "summary": "Eli Lilly and Co: * LILLY PRESENTS FIRST CLINICAL DATA FOR ITSINVESTIGATIONAL,NEXT-GENERATION FR TARGETING ADC IN PLATINUM-RESISTANT OVARIANCANCER AT THE 2025 ASCO ANNUAL MEETING ...",
    "url": "https://finnhub.io/api/news?id=7a6600ea021aceda30afbc9e8aff7784a675bad1952d2fee3ab03e28628688dc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748852588,
      "headline": "Lilly Presents First Clinical Data For Its Investigational, Next-Generation Fr?",
      "id": 134936748,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * LILLY PRESENTS FIRST CLINICAL DATA FOR ITSINVESTIGATIONAL,NEXT-GENERATION FR TARGETING ADC IN PLATINUM-RESISTANT OVARIANCANCER AT THE 2025 ASCO ANNUAL MEETING ...",
      "url": "https://finnhub.io/api/news?id=7a6600ea021aceda30afbc9e8aff7784a675bad1952d2fee3ab03e28628688dc"
    }
  },
  {
    "ts": null,
    "headline": "Grunenthal Announces Acquisition Of The Rights To Cialis From Lilly In Mexico, Brazil & Colombia",
    "summary": "Eli Lilly and Co: * GRÜNENTHAL ANNOUNCES ACQUISITION OF THE RIGHTS TO CIALIS®FROMLILLY IN MEXICO, BRAZIL & COLOMBIA * GRÜNENTHAL: FINANCIAL TERMS OF TRANSACTION ARE...",
    "url": "https://finnhub.io/api/news?id=f4a483fe79fa43b1b14039f784db18e7e25b66e3ed1a54dd54a3eae79b65984c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748852358,
      "headline": "Grunenthal Announces Acquisition Of The Rights To Cialis From Lilly In Mexico, Brazil & Colombia",
      "id": 134936684,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * GRÜNENTHAL ANNOUNCES ACQUISITION OF THE RIGHTS TO CIALIS®FROMLILLY IN MEXICO, BRAZIL & COLOMBIA * GRÜNENTHAL: FINANCIAL TERMS OF TRANSACTION ARE...",
      "url": "https://finnhub.io/api/news?id=f4a483fe79fa43b1b14039f784db18e7e25b66e3ed1a54dd54a3eae79b65984c"
    }
  },
  {
    "ts": null,
    "headline": "Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way",
    "summary": "Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY and VRTX stocks.",
    "url": "https://finnhub.io/api/news?id=25d0d9eeef0ccbe29aaac7525ee71ae6e92de5400d2db3e2c5da57290c446a18",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748852051,
      "headline": "Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way",
      "id": 134936677,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1917227251/image_1917227251.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY and VRTX stocks.",
      "url": "https://finnhub.io/api/news?id=25d0d9eeef0ccbe29aaac7525ee71ae6e92de5400d2db3e2c5da57290c446a18"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
    "summary": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
    "url": "https://finnhub.io/api/news?id=d997d158d45067defa40db36468fb001cc19cdd75b14f0315b79cb7ee1a10b7a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748850240,
      "headline": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
      "id": 134940019,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.",
      "url": "https://finnhub.io/api/news?id=d997d158d45067defa40db36468fb001cc19cdd75b14f0315b79cb7ee1a10b7a"
    }
  },
  {
    "ts": null,
    "headline": "The HealthCare Sector: A Look At Sector Earnings Trends",
    "summary": "Healthcare has been a tough sector in 2025. It looks like Q2 could be the low point for healthcare earnings growth for this year, but the sector is being buffeted by a number of headwinds.",
    "url": "https://finnhub.io/api/news?id=151bad27b00f32c17934d7f5dd806d95493549b0b885eebb4ae421d7bed8eab7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748845800,
      "headline": "The HealthCare Sector: A Look At Sector Earnings Trends",
      "id": 134935856,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189796464/image_2189796464.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Healthcare has been a tough sector in 2025. It looks like Q2 could be the low point for healthcare earnings growth for this year, but the sector is being buffeted by a number of headwinds.",
      "url": "https://finnhub.io/api/news?id=151bad27b00f32c17934d7f5dd806d95493549b0b885eebb4ae421d7bed8eab7"
    }
  }
]